Melanoma

Using an intermittent dosing strategy with vemurafenib instead of continuous dosing has the potential to overcome the development of resistance in patients with melanoma treated with the drug.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.

Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.

Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.

The anti-PD-1 therapy nivolumab demonstrated an overall objective response rate of 31%, with a median duration of 2 years in patients with advanced melanoma.

Combination therapy with ipilimumab and nivolumab led to durable tumor shrinkage in approximately half of patients with aggressive, advanced melanoma.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.

The FDA approved both dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with metastatic or unresectable melanoma.